U.S. markets closed
  • S&P 500

    4,163.29
    -10.56 (-0.25%)
     
  • Dow 30

    34,327.79
    -54.34 (-0.16%)
     
  • Nasdaq

    13,379.05
    -50.93 (-0.38%)
     
  • Russell 2000

    2,227.12
    +2.49 (+0.11%)
     
  • Crude Oil

    66.26
    -0.01 (-0.02%)
     
  • Gold

    1,867.20
    -0.40 (-0.02%)
     
  • Silver

    28.31
    +0.04 (+0.13%)
     
  • EUR/USD

    1.2158
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • GBP/USD

    1.4143
    +0.0005 (+0.04%)
     
  • USD/JPY

    109.1900
    -0.0100 (-0.01%)
     
  • BTC-USD

    43,372.71
    -2,744.22 (-5.95%)
     
  • CMC Crypto 200

    1,195.01
    -2.91 (-0.24%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Aravive to Participate in Upcoming Virtual Investor Conferences in March

  • Oops!
    Something went wrong.
    Please try again later.
Aravive, Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in March:

  • H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. Aravive’s presentation will be available for viewing on March 9, 2021.

  • Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021, at 8:00 a.m. ET

Live webcasts and audio archives of the presentations will be available at http://ir.aravive.com. Archived replays of the webcasts will be available for 90 days following the presentations.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Aravive’s lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and plans to initiate a pivotal Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company has initiated and is recruiting for its Phase 1b/2 trial in patients with clear cell renal cell carcinoma.

Contacts:
Media:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
(949) 903-4750

Investors:
Luke Heagle, W2O
lheagle@w2ogroup.com
(910) 726-1372